Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - Regular Plan - Growth
Others
Solution Oriented Index
Fund House : Edelweiss Mutual Fund
-
-
- 1W
- 2W
- 1M
- 3M
- 6M
- 1Y
- 3Y
- SI
NAV (as on
2025-06-13)
19.46 0.11%
Fund Size (Total
Assets)
-
Expense Ratio
(Regular)
1.04%
Expense Ratio
(Direct)
0.51%
SIP Returns
| Period Invested for | ₹1000 SIP Started on | Investments | Latest Value | Abs. Returns |
|---|---|---|---|---|
| One Week | 2025-06-06 | ₹1,000.00 | ₹1,017.23 |
1.72 %
|
| Two Week | 2025-05-29 | ₹1,000.00 | ₹1,032.46 |
3.25 %
|
| One Month | 2025-05-14 | ₹1,000.00 | ₹1,042.88 |
4.29 %
|
| Three Months | 2025-03-17 | ₹3,000.00 | ₹3,127.27 |
4.24 %
|
| Six Months | 2024-12-16 | ₹6,000.00 | ₹6,194.15 |
3.24 %
|
| One Year | 2024-06-13 | ₹12,000.00 | ₹12,270.53 |
2.25 %
|
| Three Year | 2022-06-14 | ₹36,000.00 | ₹47,400.73 |
31.67 %
|
| Since Inception | 2020-10-26 | ₹57,000.00 | ₹81,494.08 |
42.97 %
|
Portfolio Summary
| Company Name | Sector | Sector Type | Nav(in %) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Equity | 12.29 |
| Max Healthcare Institute Ltd. | Healthcare Services | Equity | 6.68 |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 6.03 |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Equity | 5.87 |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 5.58 |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Equity | 5.29 |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Equity | 3.41 |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.87 |
| Fortis Healthcare Ltd. | Healthcare Services | Equity | 2.65 |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.33 |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 2.29 |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.79 |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.63 |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.63 |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.57 |
| IPCA Laboratories Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.52 |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.07 |
| GlaxoSmithKline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Equity | 1.07 |
| Narayana Hrudayalaya ltd. | Healthcare Services | Equity | 0.95 |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.94 |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.90 |
| Syngene International Ltd. | Healthcare Services | Equity | 0.89 |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.84 |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Equity | 0.81 |
| Global Health Ltd. | Healthcare Services | Equity | 0.73 |
| ELI LILLY & CO | Pharmaceuticals | Debt | 4.86 |
| JOHNSON & JOHNSON | Pharmaceuticals | Debt | 3.05 |
| ABBVIE INC | Biotechnology | Debt | 2.68 |
| Novo Nordisk A/S | Pharmaceuticals & Biotechnology | Debt | 1.88 |
| ABBOTT LABORATORIES | Health Care Equipment & Supplies | Debt | 1.87 |
| NOVARTIS AG | Pharmaceuticals | Debt | 1.86 |
| INTUITIVE SURGICAL INC | Health Care Equipment & Supplies | Debt | 1.61 |
| MERCK & CO.INC | Pharmaceuticals | Debt | 1.59 |
| AMGEN INC | Biotechnology | Debt | 1.26 |
| THERMO FISHER SCIENTIFIC INC | Life Sciences Tools & Services | Debt | 1.26 |
| GILEAD SCIENCES INC | Biotechnology | Debt | 1.10 |
| STRYKER CORP | Health Care Equipment & Supplies | Debt | 1.07 |
| DANAHER CORP | Health Care Equipment & Supplies | Debt | 1.01 |
| VERTEX PHARMACEUTICALS INC | Biotechnology | Debt | 0.93 |
| MEDTRONIC PLC | Health Care Equipment & Supplies | Debt | 0.87 |
| Regeneron Pharmaceuticals Inc | Pharmaceuticals | Debt | 0.43 |
| BECTON DICKINSON AND CO | Health Care Equipment & Supplies | Debt | 0.41 |
| AGILENT TECHNOLOGIES INC | Life Sciences Tools & Services | Debt | 0.26 |
| IQVIA HOLDINGS INC | Life Sciences Tools & Services | Debt | 0.21 |
| ILLUMINA INC | Life Sciences Tools & Services | Debt | 0.11 |
| Clearing Corporation of India Ltd. | - | Debt | 0.12 |
| Net Receivables/(Payables) | - | - | -0.07 |
SIP Calculator
Risk Ratios
Standard Deviation
-
Beta
-
Sharpe Ratio
-
Lock In Period
-
Residual Maturity
-
Standard Deviation:
Standard deviation numbers measure the variability or volatility of a fund's returns over a specific time period (often 3 years).
- Low standard deviation = Stable, predictable returns → Suitable for conservative investors seeking stability.
- High standard deviation = High volatility, more risk → Be cautious, suitable for risk-tolerant investors who can handle fluctuations.
Beta:
Beta measures a fund's volatility about the market or a benchmark. A lower beta means the fund's performance is less sensitive to market movements, making it more predictable compared to the market.
- Low beta = Less sensitive to market changes → Great for investors with less market exposure.
- High beta = More sensitive to market changes → Better for aggressive investors who seek higher returns but can handle market risks.
Sharpe Ratio:
The Sharpe Ratio measures how much return a fund has made compared to the risk it carries. A higher Sharpe ratio indicates better returns relative to the risk taken, meaning the fund delivers more efficiently.
- A higher Sharpe ratio indicates better risk-adjusted returns → Look for funds with higher ratios for better return efficiency.
- Use it to compare different funds' efficiency in generating returns relative to the risk taken.
Lock-In Period:
India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.
Lock-in times for various investment types
- Most ELSS mutual fund holders hold for 3 years.
- Tax savings FDs lock in for 5 years.
- The lock-in period for 8% Government of India bond investment is 6 years.
- ULIPs must be locked in for 5 years.
- The average hedge fund holding period is 30-90 days.
- The average PPF investor holds onto their money for 15 years.
Residual Maturity:
Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.
There are two different types of residual maturity.
- Short-term residual maturity: This occurs when a security has less than a year left on its maturity.
- Long-term residual maturity: This occurs when a security has more than a year left on its remaining maturity.
Scheme Details
- Fund manager(s) : Mr. Bhavesh Jain (), Mr. Amit Vora (for investments in foreign securities) (),
- Expense ration regular : 1.04
- Expense ration direct : 0.51
- Launch date : -
- Benchmark : -
- Min SIP amount : -
- Max SIP amount : -
- Min investment amount (one time- first time) : ₹-
- Type : others
Exit load
Nil
FAQs
Is a Mutual Fund with a Lower NAV Better?
What Are the Charges in Mutual Fund Investments?
What Are the Tax Benefits of Mutual Funds?
Is It a Good Time to Invest in Mutual Funds?
What Is the Difference Between Dividend and Growth Plans?
Should I Invest in Infrastructure Funds?
What Are Sector-Specific Funds/Schemes?
What Happens If I Miss an SIP Payment?
How Can I Compare Different Mutual Funds?
Get In Touch
Interested in exploring more about JezzMoney Mutual Fund Distributors Software? Submit the form, and we will respond quickly.
Get Expert Advice on Investment in Mutual Funds!
- Certified mutual fund distributors around India will reach out to help you build your future.
- Connect with trusted mutual fund distributors and find them from your city and pincode area.
- JezzMoney is only the mediator to help you connect with these certified professionals.
- It is your obligation to gather accurate information when you receive contact from our platform.